Bio-View Ltd (TLV:BIOV)

Bio-View Statistics

Total Valuation

Bio-View has a market cap or net worth of ILS 19.16 million. The enterprise value is 13.18 million.

Market Cap	19.16M
Enterprise Value	13.18M

Important Dates

The next estimated earnings date is Sunday, November 30, 2025.

Earnings Date	Nov 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Bio-View has 134.01 million shares outstanding. The number of shares has decreased by -3.40% in one year.

Current Share Class	134.01M
Shares Outstanding	134.01M
Shares Change (YoY)	-3.40%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	50.18%
Owned by Institutions (%)	16.20%
Float	66.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.07
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.36
EV / Sales	0.74
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.30

Financial Position

The company has a current ratio of 2.60, with a Debt / Equity ratio of 0.09.

Current Ratio	2.60
Quick Ratio	1.38
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.32
Interest Coverage	-9.72

Financial Efficiency

Return on equity (ROE) is -39.31% and return on invested capital (ROIC) is -20.90%.

Return on Equity (ROE)	-39.31%
Return on Assets (ROA)	-15.89%
Return on Invested Capital (ROIC)	-20.90%
Return on Capital Employed (ROCE)	-42.75%
Revenue Per Employee	541,848
Profits Per Employee	-293,091
Employee Count	33
Asset Turnover	0.50
Inventory Turnover	1.23

Taxes

Income Tax	-748,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.48% in the last 52 weeks. The beta is -0.29, so Bio-View's price volatility has been lower than the market average.

Beta (5Y)	-0.29
52-Week Price Change	-47.48%
50-Day Moving Average	19.37
200-Day Moving Average	24.84
Relative Strength Index (RSI)	31.57
Average Volume (20 Days)	222,523

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bio-View had revenue of ILS 17.88 million and -9.67 million in losses. Loss per share was -0.07.

Revenue	17.88M
Gross Profit	8.29M
Operating Income	-9.01M
Pretax Income	-10.42M
Net Income	-9.67M
EBITDA	-8.73M
EBIT	-9.01M
Loss Per Share	-0.07

Balance Sheet

The company has 7.84 million in cash and 1.86 million in debt, giving a net cash position of 5.98 million or 0.04 per share.

Cash & Cash Equivalents	7.84M
Total Debt	1.86M
Net Cash	5.98M
Net Cash Per Share	0.04
Equity (Book Value)	19.93M
Book Value Per Share	0.15
Working Capital	11.38M

Cash Flow

In the last 12 months, operating cash flow was -5.66 million and capital expenditures -81,000, giving a free cash flow of -5.74 million.

Operating Cash Flow	-5.66M
Capital Expenditures	-81,000
Free Cash Flow	-5.74M
FCF Per Share	-0.04

Margins

Gross margin is 46.36%, with operating and profit margins of -50.37% and -54.09%.

Gross Margin	46.36%
Operating Margin	-50.37%
Pretax Margin	-58.27%
Profit Margin	-54.09%
EBITDA Margin	-48.79%
EBIT Margin	-50.37%
FCF Margin	n/a

Dividends & Yields

Bio-View does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.40%
Shareholder Yield	3.40%
Earnings Yield	-50.47%
FCF Yield	-29.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 24, 2023. It was a forward split with a ratio of 10.

Last Split Date	Dec 24, 2023
Split Type	Forward
Split Ratio	10

Scores

Bio-View has an Altman Z-Score of 1.06 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.06
Piotroski F-Score	2